uniQure (NASDAQ:QURE) Trading Up 5.8% on Analyst Upgrade

uniQure (NASDAQ:QURE)’s stock price was up 5.8% on Friday after Mizuho raised their price target on the stock from $7.00 to $20.00. Mizuho currently has a neutral rating on the stock. uniQure traded as high as $16.38 and last traded at $16.36. Approximately 193,269 shares traded hands during trading, a decline of 88% from the average daily volume of 1,651,960 shares. The stock had previously closed at $15.47.

QURE has been the topic of a number of other research reports. Royal Bank of Canada boosted their price objective on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a report on Tuesday, December 10th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. Finally, Leerink Partners upped their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.88.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently modified their holdings of the business. RTW Investments LP bought a new position in uniQure in the 3rd quarter worth about $49,000. China Universal Asset Management Co. Ltd. grew its position in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the last quarter. Atria Investments Inc bought a new position in uniQure in the 3rd quarter worth about $53,000. Quarry LP bought a new position in uniQure in the 3rd quarter worth about $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its position in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Trading Up 9.8 %

The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market cap of $827.66 million, a P/E ratio of -3.42 and a beta of 0.89. The firm’s 50-day simple moving average is $8.13 and its 200 day simple moving average is $6.77.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities research analysts anticipate that uniQure will post -3.82 earnings per share for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.